# A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

> **NCT06687941** · PHASE1 · RECRUITING · sponsor: **Aptamer Sciences, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Neoplasms
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Liver Neoplasms

## Interventions

- **DRUG:** AST-201

## Key facts

- **NCT ID:** NCT06687941
- **Lead sponsor:** Aptamer Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2027-12
- **Final completion:** 2028-05
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06687941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06687941, "A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06687941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*